Mitä Tarkoittaa RECIDIVIRAJUĆIM Englanniksi - Englanniksi Käännös

• recurrent
• relapsed

Esimerkkejä Recidivirajućim käytöstä Kroaatti ja niiden käännökset Englanti

Krhka astma je oblik astme obilježen recidivirajućim, teškim napadima.
Brittle asthma is a kind of asthma distinguishable by recurrent, severe attacks.

Za terapiju u bolesnika s recidivirajućim ili refraktornim ne-Hodgkinovim limfomom koji ne odgovara na rituksimab.
For therapy of patients with relapsed or refractory Non-Hodgkin's lymphoma not responding to rituximab.

Kyprolis u kombinaciji s lenalidomidom i deksametazonom u liječenju bolesnika s recidivirajućim multiplim mijelomom- ispitivanje PX-171-009 ASPIRE.
Kyprolis in combination with lenalidomide and dexamethasone for the treatment of patients with relapsed multiple myeloma- study PX-171-009 ASPIRE.

Podaci dobiveni na 349 bolesnika s recidivirajućim ili refraktornim, folikularnim limfomom ili transformiranim ne-Hodgkinovim limfomom niskog stupnja ispitivanih u pet studija.
Data from 349 patients with relapsed or refractory low-grade, follicular lymphoma, or transformed non-Hodgkin's lymphoma studied in five trials.

Dva daljnja ispitivanja rakova jajnika, jajovoda i peritoneuma provedena su na ukupno 845 bolesnika s recidivirajućim rakom koji se vratio nakon prethodne kemoterapije temeljene na platini.
Two further studies in ovarian, fallopian tube and peritoneal cancers were performed in a total of 845 patients with recurrent cancer that came back after previous platinum-based chemotherapy.

Za odrasle bolesnike s recidivirajućim ili refraktornim Ph+ ALL-om, monoterapija Glivecom u dozi od 600 mg/dan je sigurna, učinkovita te se može davati do pojave progresije bolesti.
For adult patients with relapsed or refractory Ph+ALL Glivec monotherapy at 600 mg/day is safe, effective and can be given until disease progression occurs.

Monoterapija lijekom Kyprolis u bolesnika s recidivirajućim i refraktornim multiplim mijelomom.
Kyprolis monotherapy in patients with relapsed and refractory multiple myeloma.

Ukupno 929 bolesnika s recidivirajućim ili refraktornim multiplim mijelomom koji su prethodno primili 1 do 3 linije liječenja uključeno je u ispitivanje i randomizirano 464 u Kd skupini; 465 u Vd skupini.
A total of 929 patients with relapsed or refractory multiple myeloma who had received 1 to 3 prior lines of therapy were enrolled and randomised 464 in the Kd arm; 465 in the Vd arm.

Ispitivanje 1 bilo je ispitivanje na jednoj skupini od 54 bolesnika s recidivirajućim folikularnim limfomom refraktornim na liječenje rituksimabom.
Study 1 was a single-arm study of 54 patients with relapsed follicular lymphoma refractory to rituximab treatment.

CLEOPATRA(WO20698) je multicentrično, randomizirano, dvostruko slijepo, placebom kontrolirano kliničko ispitivanje faze III, provedeno u 808 bolesnika s HER2 pozitivnim metastatskim ili lokalno recidivirajućim neresektabilnim rakom dojke.
CLEOPATRA(WO20698) is a multicentre, randomised, double-blind, placebo-controlled phase III clinical trial conducted in 808 patients with HER2-positive metastatic or locally recurrent unresectable breast cancer.

Toksičnost topotekana u pedijatrijskih bolesnika s recidivirajućim i refraktornim solidnim tumorima bila je slična onoj već zabilježenoj u odraslih bolesnika.
Toxicities of topotecan in paediatric patients with recurrent and refractory solid tumours were similar to those historically seen in adult patients.

Avastin se koristi u slučajevima uznapredovalog ili recidivirajućeg raka, u kombinaciji s određenim kemoterapijskim lijekovima. perzistentnim, recidivirajućim ili metastatskim rakom cerviksa vrata maternice.
Avastin is used when the cancer is advanced or recurrent, in combination with certain chemotherapy medicines; cancer of the cervix(the neck of the womb) that is persistent, recurrent or metastatic.

Rezultati djelotvornosti u bolesnika u dobi od ≥ 18 godina s recidivirajućim ili refraktornim Philadelphia kromosom negativnim ALL-om prekursora limfocita B.
Efficacy results in patients≥ 18 years of age with Philadelphia chromosome-negative relapsed or refractory B-precursor acute lymphoblastic leukaemia ALL.

Na početku je njih 60, 7% bilo kategorizirano kao AML koja nije dodatno klasificirana, 32, 4% kao AML s promjena povezanim s mijelodisplazijoma, 4, 1% kao mijeloidne novotvorine povezane s terapijom te 2, 9% kao AML s recidivirajućim genetskim abnormalnostima prema klasifikaciji SZO-a.
At baseline 60.7% were classified as AML not otherwise specified, 32.4% AML with myelodysplasia-related changes, 4.1% therapy-related myeloid neoplasms and 2.9% AML with recurrent genetic abnormalities according to the WHO classification.

Tijekom kliničkih ispitivanja, ukupno je 225 bolesnika u dobi od ≥ 18 godina s recidivirajućim ili refraktornim ALL-om prekursora B limfocita bilo izloženo lijeku BLINCYTO.
A total of 225 patients aged≥ 18 years of age with relapsed or refractory B-precursor ALL were exposed to BLINCYTO during clinical trials.

Bevacizumab je u kombinaciji s paklitakselom i cisplatinom ili, alternativno, paklitakselom i topotekanom u bolesnica koje ne mogu primiti terapiju platinom, indiciran za liječenje odraslih bolesnica s perzistentnim, recidivirajućim ili metastatskim karcinomom cerviksa vidjeti dio 5.1.
Bevacizumab, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix see Section 5.1.

BLINCYTO je procijenjen u pedijatrijskih bolesnika s recidivirajućim ili refraktornim ALL-om prekursora B limfocita u ispitivanju eskalacije doze/evaluacijskom ispitivanju faze I/II.
BLINCYTO has been evaluated in paediatric patients with relapsed or refractory B-precursor ALL in a phase I/II dose escalation/evaluation study.

Adempas je indiciran za liječenje odraslih bolesnika funkcionalnog razreda II do III prema Svjetskoj zdravstvenoj organizaciji(SZO) s inoperabilnim KTEPH-om, perzistentnim ili recidivirajućim KTEPH-om nakon kirurškog liječenja, za poboljšanje tolerancije napora vidjeti dio 5.1.
Adempas is indicated for the treatment of adult patients with WHO Functional Class(FC) II to III with inoperable CTEPH, persistent or recurrent CTEPH after surgical treatment, to improve exercise capacity see section 5.1.

Prema neovisnoj procjeni, u ispitivanju faze 2 u 225 bolesnika s lokalno recidivirajućim ili metastazirajućim karcinomom bubrega svijetlih stanica, objektivna stopa odgovora bila je 35%, a medijan trajanja odgovora bio je 68 tjedana.
In a Phase 2 study of 225 patients with locally recurrent or metastatic clear cell renal cell carcinoma, objective response rate was 35% and median duration of response was 68 weeks, as per independent review.

Bevacizumab je u kombinaciji s kemoterapijom na bazi spojeva platine indiciran za prvu liniju liječenja odraslih bolesnika s neresektabilnim uznapredovalim, metastatskim ili recidivirajućim karcinomom pluća nemalih stanica u kojemu histološki ne prevladavaju skvamozne stanice.
Bevacizumab, in addition to platinum-based chemotherapy, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer other than predominantly squamous cell histology.

U kliničkom ispitivanju u bolesnica s perzistentnim, recidivirajućim ili metastatskim karcinomom cerviksa(ispitivanje GOG-0240), gastrointestinalne perforacije(svih stupnjeva) prijavljene su u 3,2% bolesnica, a u svih njih prethodno je provedeno zračenje zdjelice.
From a clinical trial in patients with persistent, recurrent, or metastatic cervical cancer(study GOG-0240), GI perforations(all grade) were reported in 3.2% of patients, all of whom had a history of prior pelvic radiation.

Perjeta je indicirana za primjenu u kombinaciji s trastuzumabom i docetakselom u odraslih bolesnika s HER2 pozitivnim metastatskim ili lokalno recidivirajućim neresektabilnim rakom dojke koji prethodno nisu primali anti-HER2 terapiju ni kemoterapiju za liječenje metastatske bolesti.
Perjeta is indicated for use in combination with trastuzumab and docetaxel in adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease.

Ispitivanje AVF3694g bilo je multicentrično, randomizirano, placebom kontrolirano kliničko ispitivanje faze III u kojemu se ispitivala djelotvornost i sigurnost primjene lijeka Avastin u kombinaciji s kemoterapijom u odnosu na kemoterapiju plus placebo, u prvoj liniji liječenja bolesnika s HER2 negativnim metastatskim ili lokalno recidivirajućim karcinomom dojke.
Study AVF3694g was a Phase III, multicentre, randomised, placebo-controlled trial designed to evaluate the efficacy and safety of Avastin in combination with chemotherapy compared to chemotherapy plus placebo as first-line treatment for patients with HER2-negative metastatic or locally recurrent breast cancer.

Akutno zatajenje bubrega češće je prijavljivano u bolesnika s uznapredovalim recidivirajućim i refraktornim multiplim mijelomom koji su primali monoterapiju lijekom Kyprolis.
Acute renal failure was reported more frequently in patients with advanced relapsed and refractory multiple myeloma who received Kyprolis monotherapy.

Randomizirano, dvostruko slijepo, multinacionalno, placebom kontrolirano ispitivanje faze III(CHEST-1) bilo je provedeno u 261 odraslih bolesnika s inoperabilnom kroničnom tromboembolijskom plućnom hipertenzijom(KTEPH)(72%) ili perzistentnim ili recidivirajućim KTEPH-om nakon plućne endarterektomije PEA; 28.
A randomised, double-blind, multi-national, placebo controlled, phase III study(CHEST-1) was conducted in 261 adult patients with inoperable chronic thromboembolic pulmonary hypertension(CTEPH)(72%) or persistent or recurrent CTEPH after pulmonary endarterectomy PEA; 28.

Zevalin radioaktivno označen izotopom[90Y] indiciran je za liječenje odraslih bolesnika s recidivirajućim ili refraktornim CD20+ folikularnim B-staničnim ne-Hodgkinovim limfomom(NHL- om) liječenih rituksimabom.
Y-radiolabelled Zevalin is indicated for the treatment of adult patients with rituximab relapsed or refractory CD20+ follicular B-cell non-Hodgkin's lymphoma NHL.

Ispitivanje BO17704 bilo je randomizirano, dvostruko slijepo ispitivanje faze III u kojem je Avastin kao dodatak cisplatinu i gemcitabinu uspoređivan s placebom, cisplatinom i gemcitabinom u bolesnika s lokalno uznapredovalim( stadij IIIb s metastazama u supraklavikularnim limfnim čvorovima ili sa zloćudnim pleuralnim ili perikardijalnim izljevom), metastatskim ili recidivirajućim neskvamoznim karcinomom pluća nemalih stanica, koji ranije nisu primali kemoterapiju.
Trial BO17704 was a randomised, double-blind phase III trial of Avastin in addition to cisplatin and gemcitabine versus placebo, cisplatin and gemcitabine in patients with locally advanced(stage IIIb with supraclavicular lymph node metastases or with malignant pleural or pericardial effusion), metastatic or recurrent non-squamous NSCLC, who had not received prior chemotherapy.

Ispitivanje je provedeno na 143 bolesnika koji prethodno nisu primali rituksimab s recidivirajućim ili refraktornim niskostupanjskim ili folikularnim ne-Hodgkinovim limfomom(NHL-om) ili transformiranim B-staničnim NHL-om.
The trial was conducted in 143 rituximab-naïve patients with relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma(NHL), or transformed B-cell NHL.

E4599 je bilo otvoreno, randomizirano, aktivno kontrolirano, multicentrično kliničko ispitivanje u kojemu se procjenjivala primjena lijeka Avastin u prvoj liniji liječenja bolesnika s lokalno uznapredovalim(stadij IIIb sa zloćudnim pleuralnim izljevom), metastatskim ili recidivirajućim karcinomom pluća nemalih stanica u kojem histološki ne prevladavaju skvamozne stanice.
E4599 was an open-label, randomised, active-controlled, multicentre clinical trial evaluating Avastin as first-line treatment of patients with locally advanced(stage IIIb with malignant pleural effusion), metastatic or recurrent NSCLC other than predominantly squamous cell histology.

Pixuvri se ne smije primijeniti u bolesnika s aktivnom, teškom infekcijom ili u pacijenata s recidivirajućim kroničnim infekcijama u anamnezi ili koji su u takvom zdravstvenom stanju koje može pogodovati nastanku ozbiljnih infekcija.
Pixuvri should not be administered to patients with an active, severe infection or in patients with a history of recurring or chronic infections or with underlying conditions which may further predispose them to serious infection.